Dr. Hoos Discusses the Next Steps for Ipilimumab

Axel Hoos, MD, PhD
Published: Tuesday, Aug 09, 2011

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes the next steps to optimize the clinical use of ipilimumab (Yervoy) which is approved for pretreated and untreated metastatic melanoma. The drug improves survival and demonstrates durable clinical effects such as response and prolonged survival in some patients.

Hoos describes the next step is to further optimize benefits patients receive by investigating combination therapies and optimizing dosing schedules. The currently approved induction regiment is 4 doses in 3 week intervals. The drug is being examined in reinduction and as maintenance therapy. The investigation of these new schedules will help optimize ipilimumab's clinical use.
SELECTED
LANGUAGE
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, describes the next steps to optimize the clinical use of ipilimumab (Yervoy) which is approved for pretreated and untreated metastatic melanoma. The drug improves survival and demonstrates durable clinical effects such as response and prolonged survival in some patients.

Hoos describes the next step is to further optimize benefits patients receive by investigating combination therapies and optimizing dosing schedules. The currently approved induction regiment is 4 doses in 3 week intervals. The drug is being examined in reinduction and as maintenance therapy. The investigation of these new schedules will help optimize ipilimumab's clinical use.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x